TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03485937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Operative Videos
Description: Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions. The videos will be split into two modules: 1) preparing for Mohs Surgery 2) Mohs Surgery Walk through. The intervention, in the form of a video walk through, will be provided to the patient via email prior to their surgical procedure once they schedule an appointment with the Mohs clinic for their surgery day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: verbal instructions
Description: As part of the standard of care for patients receiving Mohs surgery, patients are told about the day of their surgery and what to expect

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: verbal instructions
Description: As part of the standard of care for patients receiving Mohs surgery, patients are told about the day of their surgery and what to expect

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: written instructions
Description: As part of the standard of care for patients receiving Mohs surgery, patients receive written material about the day of their surgery and what to expect

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: written instructions
Description: As part of the standard of care for patients receiving Mohs surgery, patients receive written material about the day of their surgery and what to expect
Study: NCT03635905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin (Neurontin®) is FDA-approved for the treatment of post-herpetic neuralgia and seizure disorder. Off-label uses include chronic refractory cough, neuropathy, hot flashes, restless leg syndrome, social anxiety disorder, and post-operative pain

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Methylcellulose placebo capsule
Study: NCT02147522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-care management
Description: AHH behavioral intervention is provided by promotoras
Study: NCT04815499

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement
Description: ARACOMPLEX® is an authorized food supplement that contains maca extract, vitamin complexes and ions, and that improves the quality of life of the patient.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo has a composition that makes its weight and organoleptic characteristics are identical to ARACOMPLEX®.
Study: NCT00461760

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive
Description: See Detailed Description.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive
Description: See detailed description.
Study: NCT02938949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alirocumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05571202

Intervention type: PROCEDURE
Intervention: General anesthesia plus local infiltration
Description: The eligible patients underwent anorectal surgery under general anesthesia (GE, GM, IVG) plus locally injected analgesics.

Intervention type: PROCEDURE
Intervention: Spinal anesthesia
Description: The eligible patients underwent anorectal surgery under spinal anesthesia alone.
Study: NCT00426777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate
Description: risedronate 35mg tablet, weekly for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate
Description: 35mg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: risedronate-matched placebo weekly
Study: NCT04439305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study: NCT01915654

Intervention type: PROCEDURE
Intervention: study population
Description: Population of patients undergoing cardiac surgery between December 2008 and May 2009, with pellets transfused RBCs stored for less than 14 days
Study: NCT02264418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM 203
Description: ODM 203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM 203
Description: ODM 203
Study: NCT03480919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shen Men acupuncture
Description: 20-minute acupuncture session

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Epidural injection
Description: Epidural injection for the relief of back pain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural injection
Description: Epidural injection for the relief of back pain

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Epidural injection
Description: Epidural injection for the relief of back pain
Study: NCT04572997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast was taken orally twice daily (except Day 1). Patients received tablets in blister/bottles sufficient for one month. To mitigate potential gastrointestinal side effects (primarily mild-to-moderate nausea and diarrhoea), dose titration was implemented in this study in accordance with the Summary of Product Characteristics (SmPC). A titration pack included tablets of 10, 20 and 30 mg for a period of one month. During the first 5 days, the dosage was up-titrated. The initial dose on day 1 was 10 mg in the morning; this was increased to 10 mg in the morning and evening on day 2. The evening dose was further increased by 10 mg (to 20 mg) on day 3. On day 4, the morning dose was increased to 20 mg, so that 20 mg was taken twice daily, and on day 5 the evening dose was increased to 30 mg. From Day 6 onwards, patients received the 30 mg dose twice a day. Subsequent packs included only tablets of 30 mg strength.
Study: NCT04281316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow installation
Description: Participants randomized in NHF group will receive the nasal high flow (NHF) treatment delivered by myAirvo2.~Nasal High-Flow (NHF) is a treatment delivering heated, humidified, and optionally oxygen-enriched, air at high flow rates through a nasal cannula. The physiologic effects of NHF are an improvement in gas exchanges including a reduction in hypercarbia an optimization in breathing patterns with a reduction of work of breathing and high compliance as delivered via a comfortable nasal interface

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Invasive Ventilation
Description: Participants randomized in the Non Invasive Ventilation group will receive treatment as in their usual care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training session
Description: The patients in the Nasal High Flow (MyAirvo) arm will receive two hours training adaptation session in the hospital

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education session
Description: Participants randomized in the Non Invasive Ventilation group will receive an additional educational session of one hour for improving compliance.
Study: NCT03218267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Posturography
Description: The balance platform (Good Balance by Metitur) and one leg standing test (OLS) were used to assess the static balance. OLS test was performed on left and right foot separately. The static posturography was performed with several various positions of feet. Position : normal standing with eyes open and eyes closed - an upright standing with feet placed parallel 20 cm apart for 30 s. Position: tandem - a stance with one foot placed ahead of the other for 10 s. Position: second form of tandem - a stance with one foot placed ahead of the other with feet placed on both sides of the line dividing platform to two parts for 20s. Position: one leg standing: stance on the one leg for 5 s.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Posturography
Description: The balance platform (Good Balance by Metitur) and one leg standing test (OLS) were used to assess the static balance. OLS test was performed on left and right foot separately. The static posturography was performed with several various positions of feet. Position : normal standing with eyes open and eyes closed - an upright standing with feet placed parallel 20 cm apart for 30 s. Position: tandem - a stance with one foot placed ahead of the other for 10 s. Position: second form of tandem - a stance with one foot placed ahead of the other with feet placed on both sides of the line dividing platform to two parts for 20s. Position: one leg standing: stance on the one leg for 5 s.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One-leg standing test (OLS)
Description: During the one-leg standing test (OLS) the time of maintain this position by the patients was measured. The placement of the limbs was the same as in the case of the balance platform test. Subjects performed 3 trials on each lower limb. Time ended when subject either: loosed balance and touched raised foot the floor, moved supporting leg on the ground, a significant loss of balance or a maximum of 60 s had elapsed. Results achieved by the subjects after THR on both operated (OLS-O) and non operated limbs (OLS-N) were compared with the index of the control group (OLS-C: mean result of the tests performed on the left and right legs).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One-leg standing test (OLS)
Description: During the one-leg standing test (OLS) the time of maintain this position by the patients was measured. The placement of the limbs was the same as in the case of the balance platform test. Subjects performed 3 trials on each lower limb. Time ended when subject either: loosed balance and touched raised foot the floor, moved supporting leg on the ground, a significant loss of balance or a maximum of 60 s had elapsed. Results achieved by the subjects after THR on both operated (OLS-O) and non operated limbs (OLS-N) were compared with the index of the control group (OLS-C: mean result of the tests performed on the left and right legs).
Study: NCT01890616

Intervention type: DEVICE
Intervention: SmartPill ingestion
Description: The participant would ingest the SmartPill and wear the data receiver for up to 5 days.
Study: NCT02505451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dobutamine
Description: In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dobutamine
Description: In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dobutamine
Description: In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.
Study: NCT03705000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slit Stent II
Description: The Slit-Stent II device is created by modifying the BIKA for DCR lacrimal stent through the addition of a center slit, 12 ± 1.5 mm in length, and two lateral slits 32 ± 4.5 mm in length, each having identical depth measurements to facilitate the drainage of tears. The BIKA for DCR is a sterile, single-use device that is FDA cleared as part of the BIKA family of devices under K911109..There are no changes to the raw materials used in making the modifications to the BIKA for DCR during the manufacturing of the Slit Stent II.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIKA for DCR
Description: The BIKA for DCR lacrimal stent is a bicanalicular intubation device used for intubation of the lacrimal drainage apparatus, especially in cases of dacryocystorhinostomy (conventional or laser). The silicone tube acts as a conformer during the healing process while facilitating drainage of tears through capillary action around the stent. In cases of canalicular lacerations, the silicone tube guides wound healing and prevents the onset of synechia. The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device
Study: NCT02255136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicines
Description: 5 ml dose of indicated individualized homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; twice daily for 1 year

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, in the form of a single drop of rectified spirit in 5 ml of distilled water
Study: NCT02097797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Transplantation
Description: Fecal microbiota (50-100g of stool from donor resuspended in 250-350ml of physiological serum and filtered) given by infusion in coecum during colonoscopy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transplantation
Description: 250-350ml of physiological serum given by infusion in coecum during colonoscopy
Study: NCT01870804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study: NCT06519409

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement and photodynamic therapy
Study: NCT01554176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filorexant
Description: Filorexant, one 10 mg tablet, orally, once daily at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filorexant
Description: Filorexant, one 10 mg tablet, orally, once daily at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Filorexant
Description: Filorexant, one 10 mg tablet, orally, once daily at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one tablet, orally, once daily at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one tablet, orally, once daily at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one tablet, orally, once daily at bedtime
Study: NCT04568291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: model treatment
Description: the treatment decisions were decided by Machine Learning （ML） model in model treatment group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine treatment
Description: the treatment decisions were decided by multi-disciplinary team （MDT）
Study: NCT01664832

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S-nIMV
Description: Synchronization of nasal breaths to infant's own respiratory effort

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: S-nIMV
Description: Synchronization of nasal breaths to infant's own respiratory effort
Study: NCT00718380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
Study: NCT03795935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No side-effect stimulator settings with directional lead
Description: Individuals in this arm will have their stimulator settings programmed to the point in which they have maximum tremor control with no side effects.
Study: NCT00718380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
Study: NCT01211483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287
Description: Liquid 70 mg/mL for IV infusion at high dose or low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287
Description: Liquid 70 mg/mL for IV infusion at high dose or low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tablet 150 mg for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Tablet 150 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tablet 150 mg for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid matching U3-1287 for IV infusion
Study: NCT01736605

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Patients will receive a daily 20 minute massage in their hospital room on the first 3 days following surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage combined with meditation
Description: Patients will receive a daily 20 minute massage combined with meditation in their hospital room on the first 3 days following surgery.
Study: NCT01818206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
Description: Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
Study: NCT04258540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga group
Description: The intervention group received yoga 2 times a week for 12 weeks (á 1.25 hr).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: yoga course
Description: yoga course
Study: NCT03502018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: A long-acting liposomal bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline injection used as control
Study: NCT01539395

Intervention type: OTHER
Intervention: MSDx Complex-1 Biomarker Test
Description: A biomarker test for the level of MSDx Complex-1

Intervention type: OTHER
Intervention: MSDx Complex-1 Biomarker Test
Description: A biomarker test for the level of MSDx Complex-1

Intervention type: OTHER
Intervention: MSDx Complex-1 Biomarker Test
Description: A biomarker test for the level of MSDx Complex-1
Study: NCT00581542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 1-2 drops three times a day for 8-10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polytrim
Description: 1-2 drops four times a day for 8-10 days.
Study: NCT00860249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter Only
Description: Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter and Educational DVD
Description: Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
Study: NCT00691899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: odanacatib
Description: odanacatib; 5mg oral, once daily for Approximately 36 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (unspecified)
Description: placebo; oral, once daily for Approximately 36 months
Study: NCT01890226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Personal Health Record App.
Study: NCT02707315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Study: NCT02670733

Intervention type: PROCEDURE
Intervention: Positive end-expiratory pressure
Description: Positive end-expiratory pressure will be applied at 5 cmH2O and 15 cmH2O

Intervention type: PROCEDURE
Intervention: Positive end-expiratory pressure
Description: Positive end-expiratory pressure will be applied at 5 cmH2O and 15 cmH2O